Ondansetron and Conductive deafness - a phase IV clinical study of FDA data

Summary:

Conductive deafness is reported as a side effect among people who take Ondansetron (ondansetron), especially for people who are male, also take Zofran, and have Foetal exposure during pregnancy.

The phase IV clinical study analyzes which people have Conductive deafness when taking Ondansetron. It is created by eHealthMe based on reports of 122,217 people who have side effects when taking Ondansetron from the FDA, and is updated regularly.

What is Ondansetron?

Ondansetron has active ingredients of ondansetron. It is often used in nausea. eHealthMe is studying from 122,739 Ondansetron users. Check the latest studies of Ondansetron.

What is Conductive deafness?

Conductive deafness (deafness due to a problem in conducting sound waves) is found to be associated with 54 drugs and 157 conditions by eHealthMe. Check the latest studies of Conductive deafness.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 26, 2026

122,217 people reported to have side effects when taking Ondansetron.
Among them, 16 people (0.01%) have Conductive deafness.

Could Ondansetron cause Conductive deafness?

Among these 16 people:

What is the gender of people who have Conductive deafness when taking Ondansetron? *

female: 37.5 %
male: 62.5 %

What are other drugs people take besides Ondansetron? *

Zofran: 15 people, 93.75%

What are other side effects people have besides Conductive deafness? *

Foetal Exposure During Pregnancy (exposing your unborn child to contraindicated in pregnancy leads birth defect): 16 people, 100.00%
Ear Barotrauma (discomfort and possible damage in the ear due to pressure differences between the inside and outside of the eardrum): 15 people, 93.75%
Otitis Media Chronic (long lasting inflammation of the middle ear): 14 people, 87.50%
Upper Respiratory Tract Infection: 14 people, 87.50%
Fever: 12 people, 75.00%
Sleep Apnea Syndrome: 12 people, 75.00%
Otorrhea (discharge from the ear): 11 people, 68.75%
Injury: 11 people, 68.75%
Otitis (ear infection): 11 people, 68.75%
Rhinorrhea (watery mucus discharge from the nose): 10 people, 62.50%

What are the existing conditions these people have? *

Foetal Exposure During Pregnancy (exposing your unborn child to contraindicated in pregnancy leads birth defect): 16 people, 100.00%

* Approximation only. Some reports may have incomplete information.

Do you take Ondansetron and have Conductive deafness?

- Check whether Conductive deafness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ondansetron:

Ondansetron (122,739 reports)

Browse all side effects of Ondansetron:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Conductive deafness:

Conductive deafness (54 drugs)

Browse all the conditions that are associated with Conductive deafness:

Conductive deafness (157 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ondansetron (the active ingredients of Ondansetron) and Ondansetron (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.